Trial Profile
A Multicenter, Phase 1/2 Study of Ramucirumab Plus Nivolumab as Second-line Therapy in Participants With Gastric or GEJ Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 Mar 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NivoRam study
- 25 Jan 2020 Results (data cut off of December 15, 2018) investigating the correlation of tumor mutation load and efficacy in patients with gastric cancer who received nivolumab and ramucirumab combination therapy, presented at the 2020 Gastrointestinal Cancers Symposium
- 18 Feb 2019 Status changed from active, no longer recruiting to completed.
- 19 Jan 2019 Primary endpoint has been met. (Progression free survival rate after 6 months)